Clinical Trial Detail

NCT ID NCT02876107
Title Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin

Carboplatin + Paclitaxel + Panitumumab

Carboplatin + Paclitaxel

Age Groups: adult senior

No variant requirements are available.